-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Industry News & Regulatory Approvals
-
Investigational KRAS G12D Agents Demonstrate Promising Antitumor Activity in Non-Small Cell Lung Cancer
Early findings from two clinical studies support the continued development of setidegrasib and zoldonrasib to target KRAS G12D mutations.
-
Inhaled Gene Therapy Receives FDA RMAT Designation for Advanced NSCLC
The decision was based on findings from the KYANITE-1 trial, which demonstrated that the treatment was generally well tolerated with single-agent antitumor activity observed.
-
Zongertinib Receives FDA Accelerated Approval for HER2-Mutant NSCLC
The decision marks the second approval granted under a new national priority pilot program designed to expedite the review process for drugs that are eligible for priority review.
-
In Brief for January 14, 2026
The US FDA grants special designation to risvutatug rezetecan for SCLC and approves the subcutaneous formulation of amivantamab plus hyaluronidase-lpuj for EGFR+ NSCLC.
-
In Brief for December 3, 2025
The US FDA has granted two separate approvals: one to sevabertinib for non-squamous NSCLC and another to tarlatamab-dlle for ES-SCLC.
-
In Brief for November 19, 2025
The US FDA confirms the use of pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for solid tumor indications.
-
In Brief for November 5, 2025
FDA clears a combination medication for extensive-stage small cell lung cancer for patients whose disease has not progressed after first-line induction therapy.
-
In Brief: July 23, 2025
The US FDA grants Orphan Drug Designation to CID-078 for SCLC, and zidesamtinib demonstrates positive early data in ROS1-positive NSCLC.
-
In Brief for July 9, 2025
The FDA grants accelerated approval to Dato-DXd, while a Biologics License Application for HER3-DXd is voluntarily withdrawn.
-
Research to Watch: FDA Grants ZL-1310 Fast Track Designation for Extensive-Stage SCLC
ZL-1310 earns Fast Track Designation as a potential first-in-class DLL3-targeted ADC for extensive-stage small cell lung cancer.